These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 16922655)

  • 1. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?
    Kalgutkar AS; Fate G; Didiuk MT; Bauman J
    Expert Rev Clin Pharmacol; 2008 Jul; 1(4):515-31. PubMed ID: 24410554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive listing of bioactivation pathways of organic functional groups.
    Kalgutkar AS; Gardner I; Obach RS; Shaffer CL; Callegari E; Henne KR; Mutlib AE; Dalvie DK; Lee JS; Nakai Y; O'Donnell JP; Boer J; Harriman SP
    Curr Drug Metab; 2005 Jun; 6(3):161-225. PubMed ID: 15975040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
    Prakash C; Sharma R; Gleave M; Nedderman A
    Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiosyncratic toxicity: the role of toxicophores and bioactivation.
    Williams DP; Park BK
    Drug Discov Today; 2003 Nov; 8(22):1044-50. PubMed ID: 14690635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.
    Erve JC
    Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):923-46. PubMed ID: 17125409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.
    Kalgutkar AS; Dalvie DK; O'Donnell JP; Taylor TJ; Sahakian DC
    Curr Drug Metab; 2002 Aug; 3(4):379-424. PubMed ID: 12093357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery.
    He C; Mao Y; Wan H
    Drug Discov Today; 2023 Jul; 28(7):103621. PubMed ID: 37201781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs.
    Kalgutkar AS
    Curr Med Chem; 2015; 22(4):438-64. PubMed ID: 25388012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the liabilities arising from structural alerts: a safe philosophy for medicinal chemists.
    Edwards PJ; Sturino C
    Curr Med Chem; 2011; 18(20):3116-35. PubMed ID: 21651480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing around Structural Alerts in Drug Discovery.
    Kalgutkar AS
    J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactivation of drugs: risk and drug design.
    Walsh JS; Miwa GT
    Annu Rev Pharmacol Toxicol; 2011; 51():145-67. PubMed ID: 21210745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
    Zhou S; Chan E; Duan W; Huang M; Chen YZ
    Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing metabolic activation as an integral component of drug design.
    Doss GA; Baillie TA
    Drug Metab Rev; 2006; 38(4):641-9. PubMed ID: 17145693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.